Balmer Lawrie Investments EV/EBIT
What is the EV/EBIT of Balmer Lawrie Investments?
The EV/EBIT of Balmer Lawrie Investments Limited is 1.12
What is the definition of EV/EBIT?
Enterprise value to earnings before interest and taxes (EV/EBIT) is a financial ratio used to measure if a stock is priced appropriately to similar stocks and the market. It is similar to the P/E ratio.
ttm (trailing twelve months)
The EV/EBIT ratio addresses some of the shortcomings of the P/E ratio. Instead of taking market capitalization, the ratio uses enterprise value, as it takes into account the true value of the company. Enterprise value includes both equity and debt. It is calculated as:
Enterprise value = market cap + total debt – cash and cash equivalents
The EV/EBIT ratio is useful in comparing peers within the wider market. A high EV/EBIT ratio indicates that a company’s stock is overvalued. On the opposite, a low EV/EBIT ratio indicates that a company’s stock is undervalued. The lower the ratio, the more financially stable a company should be. However, investors and analyst should use other ratios and information to get a full picture of a company’s financial state and actual value.
EV/EBIT of companies in the Finance sector on BSE compared to Balmer Lawrie Investments
What does Balmer Lawrie Investments do?
Balmer Lawrie Investments Limited, together with its subsidiaries, engages in industrial packaging, greases and lubricants, leather chemicals, logistic services and infrastructure, refinery and oil field, and travel and vacation services businesses in India. The company was incorporated in 2001 and is based in Kolkata, India.
Companies with ev/ebit similar to Balmer Lawrie Investments
- Pharos plc has EV/EBIT of 1.09
- Jindal Poly Investment and Finance has EV/EBIT of 1.10
- Olema Pharmaceuticals has EV/EBIT of 1.10
- Kronos Bio has EV/EBIT of 1.11
- Harpoon Therapeutics has EV/EBIT of 1.12
- Public Joint Stock Mining and Metallurgical Norilsk Nickel has EV/EBIT of 1.12
- Balmer Lawrie Investments has EV/EBIT of 1.12
- Abraxas Petroleum has EV/EBIT of 1.13
- Antibe Therapeutics has EV/EBIT of 1.14
- Artelo Biosciences has EV/EBIT of 1.15
- Artelo Biosciences has EV/EBIT of 1.15
- Artelo Biosciences has EV/EBIT of 1.15
- Artelo Biosciences has EV/EBIT of 1.15